Clinical trial
Diabetic Retinopathy Candesartan Trials
NCT00252733 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00252733 |
|---|---|
| Title | Diabetic Retinopathy Candesartan Trials |
| Official title | Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy. |
| Acronym | DIRECT |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | Takeda Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 1 Diabetes |
| Intervention type | Drug |
| Interventions | candesartan cilexetil |
| Enrollment | 5,238 |
| Start date | Jun 1, 2001 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Nov 15, 2005 |
| Last update posted | May 14, 2014 |
| Countries | Australia, Denmark |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: